Virginia Regulatory Town Hall
Agency
Department of Medical Assistance Services
Board
Board of Medical Assistance Services
chapter
Amount, Duration and Scope of Selected Services [12 VAC 30 ‑ 130]
Action is Exempt from Article 2 of the Administrative Process Act
Action:
Removal of DEA-X Waiver
Action 6417
 
General Information
Action Summary This action removes the federal requirement that practitioners obtain a special federal waiver, referred to as “X-Waiver” (or “DEA-X Waiver” or “Buprenorphine Waiver”) to prescribe buprenorphine for the treatment of opioid use disorder, pursuant to Section 1262 of the Consolidated Appropriations Act, 2023.
Chapters Affected Only affects this chapter.
Executive Branch Review This Action is exempt from Article 2 of the Administrative Process Act, but falls within the Executive Branch and will be reviewed by the Governor's Office.
RIS Project Yes  [7772]
Is Federal action a driving factor in this regulatory change? If so, please provide a specific reference to the law, regulation or court case.
Section 1262 of the Consolidated Appropriations Act, 2023.
New Periodic Review This action will not be used to conduct a new periodic review.
 
Stages
Stages associated with this regulatory action.
Stage ID Stage Type Status
10256 Final Final Adoption period is underway and will end on 10/23/2024.
 
Contact Information
Name / Title: Meredith Lee  / Policy, Regulations, and Manuals Supervisor
Address: 600 E. Broad St., Suite 1300
Richmond, VA 23219
Email Address: Meredith.Lee@dmas.virginia.gov
Phone: (804)371-0552    FAX: (804)786-1680    TDD: (800)343-0634